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Almost half of the U.S. population uses some
form of unconventional therapy, most without
the knowledge of their physician (1). Although
many alternative therapies are not directly
associated with adverse outcomes, unlicensed
injectable preparations may pose a significant
health risk. Outbreaks due to alternative therapies
are particularly challenging to detect, investi-
gate, and control. The difficulty is compounded
when the adverse outcome is an unusual
infection with a prolonged incubation period.
We report on a multistate outbreak of
postinjection abscesses associated with the use of
an injectable product purported to contain
adrenal cortex extract (ACE). The product was
widely distributed in the alternative medicine
community. ACE has been in use since 1895,
when William Osler reported success with a
glycerol extract of fresh adrenal tissue in the
treatment of Addison disease (2). In the 1930s,
ACE became commercially available for the
diagnosis and treatment of Addison disease and
other states of adrenal insufficiency. Synthetic
formulations of adrenal hormones replaced ACE
in general use. Although ACE never received
U.S. Food and Drug Administration (FDA)
approval, it remains in use by alternative
medicine practitioners for such conditions as
alcohol and drug withdrawal, allergies, inflam-
mation, and stress management, as well as
hypoglycemia and depression attributed to a
state of hypoadrenalism (3,4).
The Mycobacterium abscessus outbreak was
detected after two Denver-area physicians
reported soft-tissue abscesses in patients who
received injections of a product purported to
contain ACE. We determined that the cause of
the outbreaks was intrinsic contamination with
M. abscessus of vials of the product from one
distributor    (this product is hereafter referred to
as ACE*); ACE* was recalled by FDA. This
article describes the investigation of the
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An unlicensed injectable medicine sold as adrenal cortex extract (ACE*) and
distributed in the alternative medicine community led to the largest outbreak of
Mycobacterium abscessus infections reported in the United States. Records from the
implicated distributor from January 1, 1995, to August 18, 1996, were used to identify
purchasers; purchasers and public health alerts were used to identify patients.
Purchasers and patients were interviewed, and available medical records were
reviewed. Vials of ACE* were tested for mycobacterial contamination, and the product
was recalled by the U.S. Food and Drug Administration. ACE* had been distributed to
148 purchasers in 30 states; 87 persons with postinjection abscesses attributable to the
product were identified. Patient and vial cultures contained M. abscessus identical by
enzymatic and molecular typing methods. Unusual infectious agents and alternative
health practices should be considered in the diagnosis of infections that do not respond
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distribution and purchasers of ACE*; the
conditions treated with ACE*; and the occur-
rences of abscesses as well as the treatment and
clinical course of affected patients.
Methods
Epidemiologic Investigation
Passive surveillance was enhanced, and
patients and practitioners were alerted of health
risks associated with ACE* (5). We requested
invoices for purchases of ACE* from the
implicated Arizona-based distributor for Janu-
ary 1, 1995, to August 18, 1996. Purchasers were
contacted by telephone, informed of ACE*s
possible contamination, and asked to submit
remaining unopened and opened vials for
culture. A case-patient was defined as a person
who had received an injection of ACE* between
January 1, 1995, and August 18, 1996, and had
developed an abscess at the site of injection.
Purchaser and Patient Questionnaires
A standardized questionnaire was used to
collect information about the purchasers of ACE*,
their use of the product, and any adverse outcomes.
Purchasers who prescribed the product to others
or were involved in further distribution were
asked to identify persons who received ACE*.
Persons who received injections of ACE*
were identified through the distribution list,
health-care providers, and pharmacies that
dispensed ACE* directly to patients. Other
patients contacted health departments after
learning of the outbreak through news reports.
We completed a standardized questionnaire by
reviewing the medical record (whenever pos-
sible) or by interviewing the patient on the
telephone. When a practitioner declined to
disclose the patients identity, we interviewed
the practitioner to complete the patient
questionnaire. Data collected included demo-
graphic information; conditions treated with
ACE*; dosage, route, and frequency of ACE*
administration; location of ACE* injection, in a
practitioners office or at home; complications;
dates of injections, abscess onset, and seeking of
medical care; treatments given; and dates of
abscess resolution. If dosage, frequency, or
dates were not documented, the best estimate
of the provider or patient was recorded. When
only a range of doses, frequencies, or dates was
given, the midpoint was selected.
Laboratory Investigation
All purchasers and patients contacted by
CDC were asked to submit opened and unopened
vials of ACE*. FDA also collected vials for
analysis and submitted acid-fast isolates
cultured from vials to CDC for identification and
subtyping. Clinical laboratories also sampled
vials for contamination and sent isolates from
vials as well as patients to the National Jewish
Medical and Research Center. Isolates identified
as  M. abscessus were forwarded to CDC for
subtyping.
Mycobacterial cultures were performed by
aspirating 5 ml of fluid from each vial of ACE*;
0.1 ml was plated onto Middlebrook and Cohn
7H10 agar with OADC enrichment (Difco
Laboratories, Detroit, MI), and the remainder
was used to inject 40 ml of Middlebrook 7H9
broth with ADC enrichment (Difco). Mycobacte-
rial isolates were grown and identified by
methods previously described (6,7).
Isolates were typed by multilocus enzyme
electrophoresis (MEE) and pulsed-field gel
electrophoresis (PFGE) (8,9). All isolates of
mycobacteria and control strains were typed by
MEE. PFGE was used to compare three
randomly selected outbreak isolates of M.
abscessus (two vial isolates, one patient isolate)
and 27 random control isolates for their large
restriction fragment patterns with the endonu-
cleases Xba I and Dra I (9,10).
Selected isolates of M. abscessus were tested
for susceptibility to amikacin, kanamycin, and
tobramycin with disk diffusion; cefoxitin and
minocycline with agar elution; and imipenem,
ciprofloxacin, and clarithromycin with broth
microdilution (11). Three outbreak isolates of M.
abscessus and controls were tested for suscepti-
bility to mercury (12).
The Manufacturing Process and the Product
An investigation of the manufacturing
process of the product was undertaken by FDA
(13). The product was analyzed at the FDA
Forensic Chemistry Center in Cincinnati, Ohio.
Results
Abscesses Following ACE* Administration
We identified 140 persons (treated in 20
states) who received ACE* during the interval of
interest. Persons who received ACE* injections
were 15 to 77 years of age (median 43 years,683 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
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Table. Persons who received presumed adrenal cortex
extract (ACE*) and reported an abscess and persons
who received ACE* but did not develop an abscess,
United States, January 1, 1995, to August 18, 1996
Patient and Persons with Persons without
treatment    abscesses       abscesses
characteristics      (n = 87)         (n = 42)
Median age 45 years 46 years
  (Range)  (15-74)   (20-77)
Sex
  Female 81 (93%) 35 (83%)
  Male   6   (7%)   7 (17%)
Median dose   1 cc   1 cc
  (Range)   (1-2 cc)   (1-10 cc)
Dose frequency
   Single 35 (40%) 11 (26%)
  Monthly 25 (29%) 10 (24%)
Source of
 injection
  Provider 77 (89%) 34 (81%)
  Self/home   9 (10%)   8 (19%)
  Both   1   (1%)
Primary route of
 administration
  Intramuscular 86 (99%) 36 (86%)
  Intravenous   1   (1%)   6 (14%)
Intramuscular site
  Gluteal 82 (95%) 29 (69%)
  Other   4   (5%) 13 (31%)
Indicationa
 Weight loss 61 (70%) 23 (55%)
 Fatigue 11 (13%)   9 (21%)
 Hypoadrenalism   9 (10%) 10 (24%)
 Other 13 (15%)   8 (19%)
aSome persons received ACE* for more than one indication.
Figure 1. Abscesses due to Mycobacterium abscessus
on the left hip of 64-year-old man who had injected
(numerous times) a presumed adrenal cortex extract.
The first lesion developed 9 weeks before this
photograph was taken.
Figure 2. Dates of last injection of a presumed
adrenal cortex extract among persons who developed
postinjection  Mycobacterium abscessus abscesses,
United States, January 1995 to September 1996.
n = 131); 123 (88%) were women; 87 (62%)
persons from 16 states had abscesses (Figure 1);
3% had other complications: fever and chills after
injection (n = 2), acute reaction requiring
intravenous fluids (n = 1), and a tender, swollen
nodule at the site of a previous ACE* injection
that did not meet our case definition (n = 1); 42
persons reported using ACE* without adverse
effects (median follow-up 117 days, range 49-770
days); and data for 7 persons were lacking or
insufficient. The Table compares case-patients
with persons who reported that they did not
develop an abscess after using ACE*. The dates
of last injection of ACE* and onset of abscesses
are shown in Figures 2 and 3, respectively. Most
patients with abscesses had received intramus-
cular injections, though one had received an
intravenous injection; most (n = 77, 89%) had
received injections in a health-providers office.
Of the 35 case-patients who received only a
single injection of ACE*, time to noticeable
development of an abscess or documentation of
the abscess in the medical record, whichever was
earlier, was 4 to 149 days (median 32 days).
Treatment and Natural History of Abscesses
Sixty (69%) case-patients received medical
care for the abscesses, and some received more
than one type of therapy: 51 (59%) had incision684 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
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Figure 3. Dates of abscess onset in persons who had
postinjection  Mycobacterium abscessus abscesses
after using a presumed adrenal cortex extract,
United States, January 1995 to September 1996.
and drainage (14 more than once), 41 (47%) were
prescribed an antibiotic, and 11 (13%) required
surgical excision or plastic surgery. Abscesses
were cultured for mycobacteria in 21 (24%) case-
patients, 12 of whom were patients of the same
practitioner. Treatment was delayed in many
cases. Thirty-four (39%) case-patients received
either an incision and drainage procedure or a
prescription for an antibiotic active against
M. abscessus within 6 weeks of developing a
noticeable abscess. Treatment courses of
clarithromycin, in this outbreak the most
commonly prescribed antibiotic having activity
against M. abscessus (14), lasted a median of 30
days, (range 4-210 days, n = 19). Data were not
sufficient to allow a comparison of treatment
regimens.
Time to abscess resolution was estimated by
using the earliest reported or documented date of
the complication and the date on which the
abscess had resolved (on the basis of the medical
record or the patients interpretation of
resolution). Follow-up data were available on 42
(48%) case-patients. Eleven (13%) patients
reported complete resolution of abscesses during
the study period. Abscesses lasted 31 to 428 days
(median 167 days) in the 10 persons for whom we
have dates of onset and resolution. Abscesses
persisted in 31 (36%) case-patients (median
follow-up interval 217 days, range 22-672 days, n
= 30). The outcome of the remaining 45 case-
patients could not be ascertained.
Administration of ACE* by Health-Care
Providers
Of 103 health-care providers who purchased
ACE*, 58 (56%) were medical doctors, 19 (18%)
doctors of osteopathy, 17 (17%) alternative
practitioners (9 naturopaths, 6 chiropractors, 1
practitioner of homeopathic medicine, 1 holistic
practitioner); the qualifications of 9 (9%)
providers could not be determined. Providers
used ACE* most commonly for chronic fatigue
syndrome (n = 39), hypoadrenalism (n = 34),
immune system enhancement, or infection (n =
11). One physician used ACE* extensively for
weight loss. Dose per injection was 0.1 to 15 cc
(median 2 cc), most commonly as a weekly
injection (n = 31 [36%]) but ranged from a single
injection to daily injections. Providers (n = 80)
estimated treating a median of 7 patients each
with ACE* (1 to several hundred) in the
preceding 2 years. In some cases the providers
reported practice differed markedly from the
quantity of ACE* ordered. One practitioner
reported treating 12 patients with ACE* with an
average of 3.5 ml per dose on a weekly to monthly
basis, but invoices recorded that 410 (30 ml) vials
of ACE* were shipped to this practitioner over
the 20-month period.
Most providers [n = 91] administered ACE*
in their offices (n = 77 [85%]), although others
provided ACE* to their patients for home
administration. Providers (n = 89) injected ACE*
intramuscularly (n = 38 [43%]), intravenously (n
= 35 [39%]), subcutaneously (n = 2 [2%]), or by
more than one route (n = 14 [16%]). When given
intravenously, ACE* was commonly (n = 42
[47%]) mixed with other injectable preparations
including vitamins, minerals, and (in a few
cases) crude liver extract.
Laboratory Results
From at least 38 purchasers, CDC and FDA
obtained 248 vials labeled ACE. Of these, 213 vials
were tested for mycobacterial contamination
(177 unopened and 36 opened vials). M. abscessus
was cultured from 7 vials (6 unopened),
M. mucogenicum from 17 unopened vials, and
both from 1 unopened vial. The 11 patient
isolates of M. abscessus were identical to the 8 vial
isolates of M. abscessus by MEE but differed from
control isolates. Three outbreak isolates identi-
cal by MEE (data not shown) and PFGE (Figure 4)
differed from 27 control isolates. These 3 isolates
were resistant to mercury (as were the isolates of
M. mucogenicum) but susceptible to clarithromy-
cin, imipenem, amikacin, and kanamycin; moder-
ately susceptible to cefoxitin; and   resistant to
ciprofloxacin, tobramycin, and minocycline.685 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
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Figure 4. Pulsed-field gel electrophoresis patterns of
three  Mycobacterium abscessus isolates from the
outbreak (lanes 1-3), five control isolates (lanes 4-8),
and lambda DNA standards (lane 9). The
chromosomal DNA was digested with XbaI.
Tracing ACE* Distribution
All implicated vials were from the same
Arizona-based distributor. This distributor
provided 337 invoices, representing shipment of
3,954 vials (each containing 30 ml of ACE*) to
148 purchasers between January 1, 1995, and
August 18, 1996. ACE* was shipped to 30 states
and two foreign countries. Of 146 U.S.
purchasers, 103 (71%) were health-care provid-
ers, 8 (6%) were pharmacies or pharmaceutical
companies, 11 (8%) were persons who purchased
ACE* for self-administration; the remaining 24
(16%) could not be reached or declined to be
interviewed. Purchasers received shipments of 1
to 200 vials (median 6). During the period of
interest, one Dallas-based company received 13
shipments totaling 700 30-ml vials; the company
declined to provide information about further
distribution. We were able to trace 2,702 (68%)
vials distributed to either health-care providers
or persons who self-administered ACE*.
Manufacturing Process and Product
Components
According to court documents, ACE* was
manufactured in Florida under nonsterile
conditions using a handwritten formula. The
formula specified a low concentration of
hydrocortisone mixed with the powdered
preservative merthiolate (an organomercurial)
dissolved in distilled water. Samples of the
original distilled water were not available for
testing. The product was placed in unlabeled
vials and shipped to Montana, where labels
bearing the names of nonexistent pharmaceuti-
cal companies were added. Vials contained 163
µg/ml to 234 µg/ml hydrocortisone and were
found to contain mercury. There is no evidence
that adrenal glands or other animal products
were used to produce ACE* (13).
Discussion
Wide distribution of an unlicensed injectable
preparation contaminated with M. abscessus led
to a multistate outbreak of soft-tissue abscesses.
The outbreak went undetected for longer than 1
year before cases were reported to public health
authorities. Reporting led to a nationwide
investigation and recall of the implicated
product.
Nonsterile water has been suspected or
implicated in most reported outbreaks of
M. abscessus. Outbreaks have followed cardiac
surgery (15), cosmetic surgery (16), podiatric
procedures (17), invasive otologic procedures
(18), and dialysis (19,20). In most outbreaks of
postinjection abscesses due to rapidly growing
nontuberculous mycobacteria, multidose vials
appear to have become contaminated and served
as a common source (21-23). Multidose vials of
lidocaine were suspected in a recent large
outbreak in which 350 patients given injections
by an alternative medicine practitioner in
Colombia developed abscesses or skin lesions
(24,25). In this outbreak, distilled water used to
dissolve the preservative merthiolate may have
been the source of contamination. Although
approximately 80% of M. abscessus isolates are
susceptible to mercury (12), patient and vial
isolates from this outbreak were uniformly
resistant, which would explain their ability to grow
in the presence of merthiolate. M. mucogenicum
was cultured from unopened vials of ACE* but
not from patient abscesses; however, in most
cases abscesses were not cultured.
Despite a growing number of reports,
M. abscessus and other mycobacteria remain an
underappreciated cause of postinjection ab-
scesses, particularly those of long incubation
that are unresponsive to antibiotics active
against more common bacterial species. If special
culturing techniques and prolonged incubation
of culture media are not performed, the diagnosis
may not be established, and appropriate686 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
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treatment may be delayed or omitted. In this
outbreak, mycobacteria were infrequently con-
sidered by the treating physician as a possible
cause of the abscess. Only one fourth of case-
patients were documented to have had
mycobacterial cultures of an abscess; half of
these patients were under the care of a single
practitioner. Less than one third of patients with
a postinjection abscess received an antibiotic
active against mycobacteria, and most of those
received an abbreviated course unlikely to have
effected cure.
Randomized treatment trials of cutaneous
disease, including localized abscesses, due to
M. abscessus are lacking. Pretreatment isolates
are susceptible to the oral antimicrobial agent
clarithromycin (14), and most are susceptible to
the parenterally administered antibiotics
cefoxitin, imipenem, amikacin, and kanamycin
(11); however, variations in resistance patterns
make it imperative to determine the drug
susceptibilities of each clinical isolate. In the
largest reported outbreak of postinjection
abscesses, the combination of surgical excision
with clarithromycin appeared more efficacious
(53% resolution at 3 months) than either
treatment method alone (32% and 23%,
respectively) (25). Optimal therapy would
include two oral antimicrobial agents combined
with incision and drainage. When only one oral
antimicrobial agent is active against M. abscessus,
combining incision and drainage with clarithro-
mycin monotherapy may be practicable in cases
of localized soft-tissue infection. This strategy
was not associated with any adverse  complica-
tions in this outbreak. Although monotherapy
with clarithromycin has been shown to select for
resistance in disseminated M. chelonae (26-29)
and disseminated M. abscessus infections (29),
the risk appears lower in localized disease.
Clarithromycin should be continued for at least 3
to 6 months or longer depending on clinical
response (25,28).
Tracing of contaminated vials of ACE* was
hampered not only by the wide initial
distribution and the secondary distribution by
some recipients but also by the lack of lot
numbers and expiration dates on the labels. We
discovered 87 case-patients through distribution
invoices and public alerts but this number
probably underestimates the extent of the
outbreak. The role of ACE* in the development of
abscesses was underappreciated or overlooked
by patients and their health-care providers:
eight patients continued to receive injections of
ACE* after abscesses developed; one of these
received injections 8 months after the abscess
formed.
Recent interest in assessing the efficacy of
alternative medical practices in a scientifically
rigorous manner (30,31) serves the publics
health by differentiating between potentially
beneficial medicines and ineffectual or danger-
ous compounds. This report underscores not only
the dangers posed to public health by unlicensed
products from manufacturers not following good
manufacturing practices but also the delays that
can result in investigating an outbreak due to
such products. Unusual infectious agents and
alternative health practices should be consid-
ered in the diagnosis of infections that do not
respond to routine treatment.
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